We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+47.91%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$913M
AUM Growth
-$536M
Cap. Flow
+$46.2M
Cap. Flow %
5.06%
Top 10 Hldgs %
62.91%
Holding
56
New
8
Increased
8
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$25.3M
2
SLNO
Soleno Therapeutics
SLNO
+$19.4M
3
CMPS
Compass Pathways
CMPS
+$14.2M
4
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$13.3M
5
APGE icon
Apogee Therapeutics
APGE
+$8.81M

Top Sells

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$39.4M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$35.9M
3
ASLN
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
+$5.21M
4
IMUX icon
Immunic
IMUX
+$1.59M
5
CLNN icon
Clene
CLNN
+$1.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Consumer Staples 0.15%
3 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOBT
26
DELISTED
IO Biotech
IOBT
$8.7M 0.95%
6,173,439
+3,157,894
+105% +$5.55M
APGE icon
27
Apogee Therapeutics
APGE
$10.2B
$8.52M 0.93%
+400,000
New +$8.81M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$8.24M 0.9%
856,008
– –
DCTH icon
29
Delcath Systems
DCTH
$436M
$7.51M 0.82%
1,855,191
+676,404
+57% +$3.17M
SVRA icon
30
Savara
SVRA
$1.13B
$7.23M 0.79%
+1,913,349
New +$6.82M
CMPX icon
31
Compass Therapeutics
CMPX
$340M
$7.01M 0.77%
3,556,023
– –
ALLK
32
DELISTED
Allakos
ALLK
$6.78M 0.74%
2,988,000
– –
WHWK
33
Whitehawk Therapeutics
WHWK
$201M
$6.46M 0.71%
509,572
– –
ACRS icon
34
Aclaris Therapeutics
ACRS
$888M
$6.16M 0.67%
898,631
– –
TIL icon
35
Instil Bio
TIL
$49.2M
$5.34M 0.59%
624,339
– –
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.34B
$4.71M 0.52%
+777,944
New +$6.37M
BOLT icon
37
Bolt Biotherapeutics
BOLT
$7.59M
$4.03M 0.44%
193,565
– –
ARWR icon
38
Arrowhead Research
ARWR
$12.2B
$3.69M 0.4%
137,411
– –
DBVT
39
DBV Technologies
DBVT
$843M
$3.68M 0.4%
270,888
– –
SERA icon
40
Sera Prognostics
SERA
$78.3M
$3.45M 0.38%
1,856,011
– –
UNCY icon
41
Unicycive Therapeutics
UNCY
$143M
$2.98M 0.33%
+347,015
New +$3.25M
IOVA icon
42
Iovance Biotherapeutics
IOVA
$1.94B
$2.98M 0.33%
655,057
– –
ALGS icon
43
Aligos Therapeutics
ALGS
$29.3M
$2.65M 0.29%
141,881
– –
FULC icon
44
Fulcrum Therapeutics
FULC
$288M
$2.31M 0.25%
520,000
-30,000
-5% -$131K
CLNN icon
45
Clene
CLNN
$68.7M
$1.4M 0.15%
132,267
-93,764
-41% -$1.3M
IMPL
46
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$1.24M 0.14%
2,884,789
– –
ASLN
47
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.07M 0.12%
71,023
-284,091
-80% -$5.21M
BCAB icon
48
BioAtla
BCAB
$5.53M
$908K 0.1%
10,684
-2,060
-16% -$263K
CDXS icon
49
Codexis
CDXS
$156M
$734K 0.08%
388,144
– –
RZLT icon
50
Rezolute
RZLT
$451M
$639K 0.07%
484,439
-5,034
-1% -$8.21K
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return

Vivo Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Vivo Capital held 56 positions worth $913M, down 37% from $1.45B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital deployed $46.2M of net new capital in Q3 2023, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Soleno Therapeutics: 3,203,093 shares worth $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Materials.

On the sell side, the largest reduction was ASLAN Pharmaceuticals Limited American Depositary Shares, an estimated $5.21M trimmed.

  • Vivo Capital's largest Q3 2023 buy was Soleno Therapeutics: 3,203,093 shares worth $94.5M.
  • Vivo Capital added most to Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023, an estimated $25.3M increase.
  • Vivo Capital's biggest Q3 2023 reduction was ASLAN Pharmaceuticals Limited American Depositary Shares, cutting an estimated $5.21M.
  • Vivo Capital fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $39.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $913M portfolio in Q3 2023.
  • Vivo Capital opened 8 new positions and closed 3 in Q3 2023.
  • Vivo Capital's portfolio value fell 37% quarter-over-quarter to $913M.

Based on Vivo Capital's 13F filing for Q3 2023, filed 8 Nov 2023.